Julian Symons
Net worth: 148 524 $ as of 31/07/2026
Net worth: 148 524 $ as of 31/07/2026
Julian A. Symons is Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. since 2018.
Formerly, Dr. Symons was Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Education includes a doctorate from York University and an undergraduate degree from the University of Central Lancashire.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2026 | 35,112 ( 0.65% ) | 148 524 $ | 31/07/2026 |
| Companies | Position | Start |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
| Companies | Position | End |
|---|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Corporate Officer/Principal | 01/04/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Central Lancashire
University of Central Lancashire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
Select your edition
All financial news and data tailored to specific country editions